NCT02484833View on ClinicalTrials.gov

Erbitux MEtastatic Colorectal Cancer Strategy Study

PHASE3CompletedINTERVENTIONAL
Enrollment

607

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

March 31, 2020

Conditions
Antineoplastic Agents
Interventions
DRUG

Cetuximab

DRUG

FOLFIRI

Trial Locations (1)

00168

Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma

All Listed Sponsors
lead

Armando Orlandi

OTHER

NCT02484833 - Erbitux MEtastatic Colorectal Cancer Strategy Study | Biotech Hunter | Biotech Hunter